We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.4%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$4B
AUM Growth
+$287M
Cap. Flow
-$207M
Cap. Flow %
-5.17%
Top 10 Hldgs %
61.89%
Holding
76
New
7
Increased
10
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$48.1M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.8M
3
ACIU icon
AC Immune
ACIU
+$23M
4
ETNB
89bio
ETNB
+$20.2M
5
ENGN icon
enGene Therapeutics
ENGN
+$19.9M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$106M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$75.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$70.5M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.7M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.67B
$40.5M 1.01%
+1,875,000
New +$28.8M
TYRA icon
27
Tyra Biosciences
TYRA
$1.88B
$37.9M 0.95%
2,739,595
– –
LXRX icon
28
Lexicon Pharmaceuticals
LXRX
$1.03B
$37.4M 0.94%
24,435,632
+4,440,300
+22% +$5.28M
GPCR icon
29
Structure Therapeutics
GPCR
$3.33B
$33.1M 0.83%
812,988
-937,012
-54% -$53.7M
CGEM icon
30
Cullinan Oncology
CGEM
$1.01B
$32.6M 0.82%
3,196,701
– –
ANTX icon
31
AN2 Therapeutics
ANTX
$196M
$32M 0.8%
1,563,963
– –
ANNX icon
32
Annexon
ANNX
$832M
$31.8M 0.8%
+7,000,000
New +$17.3M
ROIV icon
33
Roivant Sciences
ROIV
$24.4B
$30.8M 0.77%
2,742,409
– –
SLN
34
Silence Therapeutics
SLN
$527M
$26.2M 0.66%
1,508,416
– –
ALLK
35
DELISTED
Allakos
ALLK
$23.3M 0.58%
8,552,417
– –
CBIO
36
Crescent Biopharma
CBIO
$525M
$22.5M 0.56%
95,443
– –
OVID icon
37
Ovid Therapeutics
OVID
$420M
$22.1M 0.55%
6,851,051
– –
ENGN icon
38
enGene Therapeutics
ENGN
$117M
$20.8M 0.52%
+2,251,037
New +$19.9M
CALT
39
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$19.3M 0.48%
750,000
– –
TCRX icon
40
TScan Therapeutics
TCRX
$48.4M
$17.4M 0.44%
2,989,474
– –
NAMS icon
41
NewAmsterdam Pharma
NAMS
$3.24B
$17M 0.43%
1,521,948
– –
SYRE icon
42
Spyre Therapeutics
SYRE
$8.47B
$14.8M 0.37%
+687,080
New +$9.47M
STRO icon
43
Sutro Biopharma
STRO
$402M
$14.4M 0.36%
334,795
– –
ITOS
44
DELISTED
iTeos Therapeutics
ITOS
$13.8M 0.35%
1,259,476
– –
VSTM icon
45
Verastem
VSTM
$496M
$13.7M 0.34%
1,685,219
– –
IMVT icon
46
Immunovant
IMVT
$7.87B
$12.6M 0.32%
300,000
– –
VTGN icon
47
VistaGen Therapeutics
VTGN
$9.78M
$10.3M 0.26%
+2,000,000
New +$7.57M
CTMX icon
48
CytomX Therapeutics
CTMX
$686M
$10.2M 0.26%
6,595,801
– –
IMA
49
ImageneBio Inc
IMA
$63.6M
$9.4M 0.24%
397,430
+133,333
+50% +$4.35M
VERV
50
DELISTED
Verve Therapeutics
VERV
$9.06M 0.23%
650,000
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2023 Portfolio in Review

As of Q4 2023, BVF Inc held 76 positions worth $4B, up 7.7% from $3.71B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $207M in Q4 2023, closing 6 positions and reducing 7 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $70.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Syndax Pharmaceuticals worth $40.5M.

  • BVF Inc's largest Q4 2023 buy was Syndax Pharmaceuticals: 1,875,000 shares worth $40.5M.
  • BVF Inc added most to Revolution Medicines in Q4 2023, an estimated $48.1M increase.
  • BVF Inc's biggest Q4 2023 reduction was IDEAYA Biosciences, cutting an estimated $106M.
  • BVF Inc fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $70.5M.
  • BVF Inc's ten largest holdings make up 62% of its $4B portfolio in Q4 2023.
  • BVF Inc opened 7 new positions and closed 6 in Q4 2023.
  • BVF Inc's portfolio value rose 7.7% quarter-over-quarter to $4B.

Based on BVF Inc's 13F filing for Q4 2023, filed 14 Feb 2024.